Here you will find all our clinical education resources from articles to recorded webinars, all supporting equitable access to funded medicines.
Our free Continuous Quality Improvement Toolkit can help you to complete the Cornerstone CQI module, fulfill Foundation Standard criteria, make the most of the EPiC dashboard, and change practices that may be contributing to health inequities.
Liraglutide (Victoza brand only) joins dulaglutide as a funded GLP-1 receptor agonist for treating type 2 diabetes. This piece of microlearning outlines the differences and similarities between the two medicines.
Phenobarbitone tablets are undergoing a brand change. In order to transition patients with epilepsy to the new brand safely, action is required as soon as practicable by both the healthcare professional and patient
Manage patient expectations for antibiotics with our Virus Action Plans for adults and children. These concise, editable information sheets help to reinforce when symptomatic and supportive care is the best medicine for your patient.
Available in Arabic, English, Māori, Hindi, Samoan, simplified Chinese and Tongan.
This piece of microlearning quotes results from the Youth19 Rangatahi Smart Survey, which shows that depression rates among young New Zealanders have risen.
For uncomplicated lower UTIs, often referred to as cystitis, using the right antibiotic for the right duration is the best way to ensure appropriate, effective treatment and avoid development of antimicrobial resistance. This case study illustrates the recommended treatment for a symptomatic, uncomplicated UTI.
On 1 March 2023, liraglutide (Victoza brand) became the second GLP-1 receptor agonist (GLP1RA) funded in Aotearoa New Zealand. This article and accompanying algorithm PDF have been developed to help prescribers through the process of starting dulaglutide or liraglutide in eligible patients with type 2 diabetes.
Despite limited indications, amoxicillin + clavulanic acid remains the second most used antibiotic in Aotearoa after amoxicillin. Inappropriate use of antibiotics may stem partly from meeting patient expectations for treatment. Read our case study to find out more.
This video is a recording of the live webinar hosted by He Ako Hiringa on 6 March 2023. Drs Sarah Sciascia, Bronwen Chesterfield, Kyle Eggleton and Lucy O’Hagan discuss racism, prescribing bias, cultural safety and pro-equity practice.
Episode six of our Legendary Conversations podcast continues our discussion with Lauren Smith, senior practice fellow at the University of Otago School of Pharmacy. In this episode, Lauren uses an impetigo case study to clarify the appropriate use of topical antibiotics.
This piece of microlearning supports the use of topical antiseptics rather than topical antibiotics for common, minor skin infections.
This video is a recording of the live webinar hosted by He Ako Hiringa on 23 February 2023. Pharmacist researchers Joanna Hikaka, Nora Parore and Brendon McIntosh explore Māori experiences and perceptions of care for minor ailments, and how to incorporate solutions into your daily practice.